STEAP1 CAR T Therapy: A Paradigm Shift in Prostate Cancer

STEAP1 CAR T Therapy: A Paradigm Shift in Prostate Cancer

Metastatic castration-resistant prostate cancer (mCRPC) remains one of the most difficult cancers to treat, with limited therapeutic options and poor patient outcomes.

‍STEAP1 (Six Transmembrane Epithelial Antigen of the Prostate 1) has emerged as a highly promising target, given its over expression in approximately 88% of lethal mCRPC cases, compared to 60% for PSMA.

Unlike traditional therapies, targeting STEAP1 offers a broader and more effective approach to combating aggressive prostate cancer.

‍

The Potential of STEAP1 CAR T Therapy

PromiCell’s STEAP1 CAR T therapy represents a breakthrough in prostate cancer treatment by overcoming key challenges faced by previous immunotherapies:

• Enhanced Durability & Efficacy – Incorporates IL-18 armoring to strengthen immune response and improve CAR T-cell persistence.
• Optimized Design – Engineered to function effectively even in low-antigen density environments, a major hurdle for other CAR T therapies.
• Clinical Promise – Preclinical models have shown complete tumor regression within five weeks, and ongoing clinical trials suggest promising early results.

‍

‍

While prior CAR T therapies targeting PSMA and PSCA have faced limitations, including adverse effects and poor response rates, STEAP1-based treatments present a safer, more precise, and more effective alternative.

‍

To explore the full potential of STEAP1-targeted therapy and how it extends beyond prostate cancer to other malignancies, read the detailed analysis here:

https://www.news-medical.net/whitepaper/20250117/The-evolution-of-STEAP1-targeted-therapy.aspx

‍